PR91548

BEIJING and BRIDGEWATER, N. J., Sept. 9, 2021 /PRNewswire=KYODO JBN/ --

Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee,

stock code: 603087.SH), is excited to present positive data from five abstracts

which will be featured as short oral discussions at the 57th Annual European

Association for the Study of Diabetes (EASD) Meeting. The meeting will be held

virtually from September 27th – October 1st, 2021.

The following new data will be presented on September 30th, 2021, 11:45 – 13:15

CEST:

- Novel GLP-1 analogue, GZR18: a preclinical evaluation in type 2 diabetes

models

- Phase 3 confirmatory study comparing efficacy and safety of proposed

biosimilar and reference insulin aspart, combined with metformin, in patients

with diabetes

In addition, recent results from our encore Phase 1 clinical trials will also

be presented on September 30th, 2021, 11:45 – 13:15 CEST:

- Proposed biosimilar insulin aspart (GL-ASP) shows pharmacokinetic (PK) and

pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin

aspart

- Proposed biosimilar insulin lispro (GL-LIS) shows pharmacokinetic (PK) and

pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin

lispro  

- Proposed biosimilar insulin glargine (GL-GLA) shows pharmacokinetic (PK) and

pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin

glargine

The data that will be presented at the EASD Annual Meeting, are important

milestones for the clinical development programs at Gan & Lee. Furthermore, the

abstracts mentioned above demonstrate Gan & Lee's dedication to providing

solutions for patients with diabetes. "We are pleased to have all five

abstracts published by the EASD as we continue to seek scientific solutions for

diabetes care", said Michelle Mazuranic, Head of Global Medical Affairs. The

presentation numbers for GZR18, GL-ASP (Phase 3 in China), GL-ASP (Phase 1),

GL-LIS, and GL-GLA are 463, 513, 510, 514, and 511, respectively.

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic

human insulin. Currently, we have five recombinant insulin analogs

commercialized in China including long-acting glargine injection (Basalin®),

fast-acting lispro injection (Prandilin(TM)), fast-acting aspart injection

(Rapilin(R)), mixed protamine zinc lispro injection (25R) (Prandilin(TM)25),

aspart 30 injection (Rapilin®30), and one human insulin injection approved in

China - mixed protamine human insulin injection (30R) (Similin®30). We have two

approved medical devices in China, namely reusable insulin injection pen

(GanleePen), and disposable pen needle (GanleeFine®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the

field of diabetes diagnosis and treatment. Moving forward to advance our goal

of becoming a world-class pharmaceutical company, we will also take an active

part in developing new chemical entities, and working on the treatment of

cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.

For more information, please contact us at investorrelations@ganlee.us.

References:

Leona Plum- Mörschel, et. al. Proposed biosimilar insulin aspart (GL-ASP) shows

pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and

EU-authorised insulin aspart. Diabetes. June 22, 2021.

Eric Zijlstra, et. al. Proposed biosimilar insulin lispro (GL-LIS) shows

pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and

EU-authorised insulin lispro. Diabetes. June 22, 2021.

Tim Heise, et. al. Proposed biosimilar insulin glargine (GL-GLA) shows

pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and

EU-authorised insulin glargine. Diabetes. June 22, 2021.

Gina Antonucci, #: 888-288-5395, investorrelations@ganlee.us  

Source: Gan & Lee Pharmaceuticals Co., Ltd.